Promising new combo targets stubborn ovarian cancer
NCT ID NCT06494150
First seen Feb 16, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study tests a combination of two drugs—nab-sirolimus and fulvestrant—in people whose low-grade serous ovarian cancer has returned. The goal is to see if the combo can shrink tumors or stop them from growing. About 37 adults with measurable disease will take part, and researchers will track how many respond and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE OVARIAN SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73117, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.